AB155976

Anti-Cdk7 (phospho T170) antibody [EPR6650(2)]

20ul selling size
RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(5 Publications)

Rabbit Recombinant Monoclonal CDK7 phospho T170 antibody. Suitable for WB and reacts with Mouse, Rat, Human samples. Cited in 5 publications.

View Alternative Names

CAK, CAK1, CDKN7, MO15, STK1, CDK7, Cyclin-dependent kinase 7, 39 kDa protein kinase, CDK-activating kinase 1, Cell division protein kinase 7, Serine/threonine-protein kinase 1, TFIIH basal transcription factor complex kinase subunit, p39 Mo15

5 Images

Lab

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (ab155976) at 1/1000 dilution

Lane 1:

HeLa cell lysate (untreated) at 10 µg

Lane 2:

HeLa cell lysate (treated with Lambda phosphatase) at 10 µg

Secondary

All lanes:

Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Predicted band size: 39 kDa

Observed band size: 39 kDa

false

Lab

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (ab155976) at 1/1000 dilution

All lanes:

A431 cell lysate at 20 µg

Secondary

All lanes:

Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Predicted band size: 39 kDa

Observed band size: 39 kDa

false

Lab

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (ab155976) at 1/1000 dilution

Lane 1:

C6 cell lysate at 10 µg

Lane 2:

Rat spleen tissue lysate at 10 µg

Secondary

All lanes:

Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Predicted band size: 39 kDa

Observed band size: 39 kDa

false

Lab

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Blocking buffer and concentration : 5% NFDM/TBST.

Diluting buffer and concentration : 5% NFDM /TBST.

All lanes:

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (ab155976) at 1/1000 dilution

All lanes:

NIH/3T3 cell lysate at 20 µg

Secondary

All lanes:

Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/1000 dilution

Predicted band size: 39 kDa

Observed band size: 39 kDa

false

Unknown

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

All lanes:

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (ab155976) at 1/1000 dilution

Lane 1:

HeLa cell lysate (untreated) at 10 µg

Lane 2:

HeLa cell lysate (treated with Lambda phosphatase) at 10 µg

Predicted band size: 39 kDa

false

Carrier free

Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR6650(2)

Isotype

IgG

Carrier free

Reacts with

Mouse, Rat, Human

Applications

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "For unpurified use at 1/1000 - 1/10000.", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "For unpurified use at 1/1000 - 1/10000.", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "For unpurified use at 1/1000 - 1/10000.", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cyclin-dependent kinase 7 (Cdk7) also known as CAK is a protein that functions as a serine/threonine kinase. It has a mass of approximately 37 kDa and is expressed in various tissues including the liver heart and testis. Cdk7 forms part of the CDK-activating complex required for the cell cycle's progression and transcription processes. By phosphorylating important sites on target proteins Cdk7 contributes to the regulation of the cell cycle and RNA polymerase II-mediated transcription.

Biological function summary

Cdk7 interacts with other molecules playing a fundamental role in the regulation of cell division and transcription. Cdk7 is a component of the Cdk-activating kinase (CAK) complex alongside cyclin H and MAT1. This complex enables activation of other cyclin-dependent kinases through phosphorylation which is essential for DNA replication and repair. As part of the transcription complex TFIIH Cdk7 enhances RNA polymerase II's transcriptional activity influencing gene expression and cellular responses to external signals.

Pathways

Cdk7 participates in significant regulatory pathways controlling cell cycle and transcription. It is integral to the p53 Signaling and Cell Cycle pathways where it facilitates the activation of CDK1 CDK2 and CDK4/6 key players in cell cycle progression from the G1 to S phase. Through these pathways Cdk7 maintains cellular control upon environmental stress responses and DNA damage providing connections to tumor suppressor proteins such as p53.

Cdk7 has associations with cancer and neurodegenerative diseases. Its dysregulation can lead to unchecked cell proliferation contributing to the development of various cancers like breast and lung cancer. Cdk7's role in transcription implicates it in disorders like Alzheimer's disease where altered transcriptional regulation is observed. Furthermore its interaction with proteins such as p53 links it to cancer as p53 mutations can result in the loss of control over the cell cycle exacerbating tumorigenic processes.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts (PubMed : 9852112). Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.

See full target information CDK7 phospho T170

style

left-column

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

NPJ breast cancer 11:39 PubMed40287441

2025

MUC1-C dependency in drug resistant HR+/HER2- breast cancer identifies a new target for antibody-drug conjugate treatment.

Applications

Unspecified application

Species

Unspecified reactive species

Ayako Nakashoji,Atrayee Bhattacharya,Hiroki Ozawa,Naoki Haratake,Keisuke Shigeta,Atsushi Fushimi,Nami Yamashita,Akira Matsui,Shoko Kure,Tomoe Kameyama,Makoto Takeuchi,Kazumasa Fukuda,Takamichi Yokoe,Aiko Nagayama,Tetsu Hayahsida,Yuko Kitagawa,Renyan Liu,Antonio Giordano,Rinath Jeselsohn,Geoffrey I Shapiro,Donald Kufe

Virus research 335:199200 PubMed37591314

2023

Cytomegalovirus cyclin-dependent kinase ortholog vCDK/pUL97 undergoes regulatory interaction with human cyclin H and CDK7 to codetermine viral replication efficiency.

Applications

Unspecified application

Species

Unspecified reactive species

Martin Schütz,Christina Wangen,Mona Sommerer,Melanie Kögler,Jan Eickhoff,Carsten Degenhart,Bert Klebl,Zin Naing,Ece Egilmezer,Stuart T Hamilton,William D Rawlinson,Heinrich Sticht,Manfred Marschall

Frontiers in oncology 13:1051516 PubMed36776326

2023

14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression.

Applications

Unspecified application

Species

Unspecified reactive species

S Breedy,W S Ratnayake,L Lajmi,R Hill,M Acevedo-Duncan

Nature communications 10:5444 PubMed31784510

2019

A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Chiara Ghezzi,Alicia Wong,Bao Ying Chen,Bernard Ribalet,Robert Damoiseaux,Peter M Clark

Oncogene 38:3616-3635 PubMed30651597

2019

Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair.

Applications

Unspecified application

Species

Unspecified reactive species

Marcos Seoane,Sophia Buhs,Pablo Iglesias,Julia Strauss,Ann-Christin Puller,Jürgen Müller,Helwe Gerull,Susanne Feldhaus,Malik Alawi,Johanna M Brandner,Dennis Eggert,Jinyan Du,Jürgen Thomale,Peter J Wild,Martin Zimmermann,Thomas Sternsdorf,Udo Schumacher,Peter Nollau,David E Fisher,Martin A Horstmann

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-Cdk7 (phospho T170) antibody [EPR6650(2)]

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Western blot - Anti-Cdk7 (phospho T170) antibody [EPR6650(2)] (AB155976)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (5)

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Product promise